Business
Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights
- Cash and cash equivalents totaled approximately $286 million at March 31, 2020 - - Rolling submission of voclosporin New Drug Application to the U.S. Food
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\n- Cash and cash equivalents totaled approximately $286 million at March 31, 2020 -\n\n\n- Rolling submission of voclosporin New Drug Application to the U.S. Food & Drug Administration remains on track for completion by the end of the second quarter 2020 – \n\n\n- Continued evolution into commercial-stage organization highlighted by the appointments of Timothy P Walbert to the Board, Max Colao as Chief Commercial Officer, and Joe Miller as Chief Financial Officer –\n\n\n- Conference call and webcast to be hosted today at 4:30pm EDT -\n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.\n\n\n“We are fortunate that the global COVID-19 pandemic has had minimal impact on Aurinia’s operations, and we have maintained our timelines to ensure the filing of the voclosporin NDA by the end of the second quarter and hopefully obtain approval in early 2021,” commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Following the positive AURORA data reported last December we have strengthened the balance sheet, added world-class commercial expertise including the appointments of Timothy, Max, and Joe, and on-boarded a group of extraordinarily talented commercial leaders and additional staff.”\n\n\nMr. Greenleaf further stated, “With the establishment of our commercial hub in Maryland, we’re building and preparing for the U.S. launch of voclosporin as the first FDA-approved treatment for lupus nephritis. In addition, the VOS development program remains on target, and we anticipate reporting out top-line results from the Phase 2/3 AUDREY dose-ranging trial of VOS during the fourth quarter of this year.”\n\n\nDr. Neil Solomons, Chief Medical Officer of Aurinia commented, “With respect to FSGS, our exploratory study has been open for an extended period and due to the continued difficulty identifying and enrolling primary FSGS patients, we’ve decided to adjust our approach. We are preparing to evaluate voclosporin in other proteinuric kidney diseases, while continuing to support patients who have participated in the FSGS exploratory study. As we wor...